Scholarlink

Purpose of Review <p>This article will review several cases demonstrating breast imaging findings following the use of glucagon-like peptide-1 (GLP-1) agonists, including the relevant implications in changing breast density and supplemental screening.</p> Recent Findings <p>GLP-1 agonists may be associated with breast changes and symptoms that warrant further breast imaging, including supplemental screening and/or for problem solving in the appropriate clinical scenario.</p> Summary <p>Breast imaging findings following the use of GLP-1 agonists may vary, including both significant and insignificant increases in breast density. Patients with increased breast density may warrant further evaluation with supplemental screening. Following the use of GLP-1 agonists, patients may also present with symptoms warranting further targeted imaging evaluation. Knowledge of the spectrum of breast changes associated with GLP-1 agonists is necessary to adequately assess the need for supplemental screening and/or additional targeted breast imaging.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Case-Based Review of Breast Imaging Changes Associated With GLP-1 Agonists

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月14日

查看全文
  • Joseph J. Villavicencio,
  • Samantha P. Zuckerman

摘要

Purpose of Review

This article will review several cases demonstrating breast imaging findings following the use of glucagon-like peptide-1 (GLP-1) agonists, including the relevant implications in changing breast density and supplemental screening.

Recent Findings

GLP-1 agonists may be associated with breast changes and symptoms that warrant further breast imaging, including supplemental screening and/or for problem solving in the appropriate clinical scenario.

Summary

Breast imaging findings following the use of GLP-1 agonists may vary, including both significant and insignificant increases in breast density. Patients with increased breast density may warrant further evaluation with supplemental screening. Following the use of GLP-1 agonists, patients may also present with symptoms warranting further targeted imaging evaluation. Knowledge of the spectrum of breast changes associated with GLP-1 agonists is necessary to adequately assess the need for supplemental screening and/or additional targeted breast imaging.